Home > Press > Arrowhead Subsidiary, Unidym, Establishes Headquarters in Silicon Valley
Arrowhead Research Corporation (NASDAQ:ARWR) announced today that its majority-owned subsidiary, Unidym, Inc., a developer of carbon nanotube electronics, has established a 7,000 sq. ft. office and lab facility in Menlo Park, California in the heart of Silicon Valley.
Arrowhead Subsidiary, Unidym, Establishes Headquarters in Silicon Valley
PASADENA, CA | Posted on February 8th, 2007
"This move puts Unidym in close proximity to many of its potential customers and collaborators," said R. Bruce Stewart, Arrowhead's Chairman. "The Silicon Valley is a global center of the electronics industry and Unidym can draw from the local talent pool of expertise and experience in the development and commercialization of cutting edge electronics applications."
Unidym's initial product is a thin, transparent film of carbon nanotubes designed to replace the expensive, failure-prone materials currently employed by manufacturers of devices such as touch screens, flat panel displays, and solid state lighting. Unidym's technology is also useful for the production of novel carbon nanotube-based transistors and conductive inks for the printable electronics industry which could enable the replacement of today's complex and capital intensive semiconductor manufacturing processes with inexpensive, solution-based printing processes. Unidym differentiates itself through its emphasis on low-cost materials and processes, in-house carbon nanotube production, aggressive partnership strategy, and a significant intellectual property portfolio that includes foundational IP in both transparent electrodes and thin film transistors.
Arrowhead has an 88% stake in Unidym.
About Arrowhead Research Corporation
Arrowhead Research Corporation ( http://www.arrowheadresearch.com ) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
For more information, please click here
Arrowhead Research Corporation
Virginia E. Dadey, 212-541-3707
Copyright © Business Wire
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Harris & Harris Group Reports Financial Statements as of December 31, 2014 and Posts Annual Letter to Shareholders on Website March 17th, 2015
Arrowhead to Present at 2015 Barclays Global Healthcare Conference March 4th, 2015
Arrowhead to Present at 2015 RBC Capital Markets' Global Healthcare Conference February 17th, 2015
Iran 1st among Islamic Nations in Scientific Production, Nanotechnology February 16th, 2015
Rutgers, NIST physicists report technology with potential for sub-micron optical switches March 31st, 2015
Prototype 'nanoneedles' generate new blood vessels in mice: Scientists have developed tiny 'nanoneedles' that have successfully prompted parts of the body to generate new blood vessels, in a trial in mice March 31st, 2015
Super sensitive measurement of magnetic fields March 31st, 2015
Nanomedicine pioneer Mauro Ferrari at ETH Zurich March 31st, 2015
2015 Nanonics Image Contest January 29th, 2015
OCSiAl supports NanoART Imagery Contest January 23rd, 2015
EnvisioNano: An image contest hosted by the National Nanotechnology Initiative (NNI) January 22nd, 2015
Oxford Instruments Asylum Research Announces AFM Image Contest Winners January 11th, 2015